The H19 Long non-coding RNA in cancer initiation, progression and metastasis - a proposed unifying theory.

Raveh E, Matouk IJ, Gilon M, Hochberg A. · 2015

Read The H19 Long non-coding RNA in cancer initiation, progression and metastasis - a proposed unifying theory. by Raveh E, Matouk IJ, Gilon M, Hochberg A. (2015) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc4632688.txt.

Introduction

Eli Raveh, together with colleagues, released a 2015 review proposing a unifying theory for H19, a long non-coding RNA tied to cancer. H19 is active in the embryo, switches off at birth, and reappears in almost every human cancer. Past studies disagreed on whether it helps or hinders tumours. The review appeared in Oncotarget.

The authors argue that H19 pushes stressed cells into a selfish survival mode, speeding growth and raising stress resistance, often alongside loss of the tumour suppressor P53. H19 also takes part in cell identity changes that drive spread, in both directions. Seen this way, its seemingly opposite effects fit one picture: the tumour uses H19 differently at each stage of progression. The theory aims to settle long-running disputes in the field.

Catalog record

CREATORRaveh E, Matouk IJ, Gilon M, Hochberg A.
YEAR2015
COLLECTIONPAPERS
FORMATTXT
FILE SIZE70 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC4632688

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

The H19 Long non-coding RNA in cancer initiation, progression and metastasis – a proposed unifying theory By Eli Raveh, Imad J Matouk, Michal Gilon, Abraham Hochberg Published in: Molecular Cancer DOI: 10.1186/s12943-015-0458-2 ABSTRACT Abstract The imprinted oncofetal long non-coding RNA (lncRNA) H19 is expressed in the embryo, down-regulated at birth and then reappears in tumors. Its role in tumor initiation and progression has long been a subject of controversy, although accumulating data suggest that H19 is one of the major genes in cancer. It is actively involved in all stages of tumorigenesis and is expressed in almost every human cancer. In this review we delineate the various functions of H19 during the different stages in the complex process of tumor progression. H19 up-regulation allows cells to enter a “selfish” survival mode in response to stress conditions, such as destabilization of the genome and hypoxia, by accelerating their proliferation rate and increasing overall cellular resistance to stress. This response is tightly correlated with nullification, dysfunction or significant down-regulation of the master tumor suppressor gene P53. The growing evidence of H19’s involvement in both proliferation and differentiation processes, together with its involvement in epithelial to mesenchymal transition (EMT) and also mesenchymal to epithelial transition (MET), has led us to conclude that some of the recent disputes and discrepancies arising from current research findings can be resolved from a viewpoint supporting the oncogenic properties of H19. According to a holistic approach, the versatile, seemingly contradictory functions of H19 are essential to, and differentially harnessed by, the tumor cell depending on its context within the process of tumor progression. Keywords: H19, miR-675, Tumorigenesis, Proliferation, Differentiation, EMT, MET, Genomic instability, miR-200, let-7 BACKGROUND Tumorigenesis is a multistep process that involves both the neoplastic tissue and its surroundings. In order to survive and flourish, cancer cells acquire a unique genetic background, proliferate rapidly, evade growth suppressors, cell death pathways and immune system attacks, and resist multiple drug treatments. Cancer cells are experts in managing hypoxia and stress conditions by recruiting blood supply to the neoplastic tissue, adjusting metabolically and adopting the plasticity that should enable epithelial to mesenchymal transition (EMT), metastasis and colonization at secondary sites [1]. In many aspects, a cancer cell resembles an embryonic cell: they share extraordinary plasticity, proliferation, motility and invasiveness capabilities, as well as the ability to make metabolic adjustments and other attributes, all orchestrated by common molecular pathways and epigenetic patterns [2]. One of the pivotal players in both embryonic development and tumorigenesis is the oncofetal lncRNA gene H19. H19, a maternally expressed and paternally imprinted 2.7 kb gene, resides close to the telomeric region of chromosome 11p15.5 and is reciprocally imprinted and regulated with its neighboring gene IGF2. Its genomic locus is rich in transcript coding sequences residing on both strands, as we have discussed elsewhere [3]. However, one of the most important transcripts in the H19 locus is miR-675, a highly conserved micro-RNA that resides within exon-1 of the H19 gene. Recent studies have highlighted the important roles of H19 during the complex process of tumorigenesis, starting from the early stages that involve translational deregulation and genomic instability, through proliferation imbalance and stress management to metastasis. In this article we review the role of H19 in the tumorigenic multistep process and show how H19 touches almost every aspect of tumorigenesis. We also describe how H19 functions as an initial tumorigenic output component in the mammalian feedback system responding to various stress conditions. We suggest a general unifying theory that may answer some of the disputes and discrepancies that have arisen in regard to the fundamental characteristics of the H19 gene. H19 MECHANISM OF ACTION H19 has a highly conserved secondary structure. This evolutionary conservation suggests that H19's function is structure-dependent [4]. H19's function can be dissected into two major functions; a reservoir of miR-675 that suppresses its targets [5, 6], and a modulator of micro-RNAs or proteins via their binding. MiR-675 targets a myriad of transcripts in a cellular-context-dependent manner [5]. For example, miR-675 directly downregulates Igf1r [5], Smad1, Smad5, and Cdc6 [7],Cadherin-11 [8], Cadherin-13 [9], Rb [10], Runx1 [11], Nodal Modulator 1 [12], TGFBI [13] CALN1 [14], and MITF [15]. Indirect targets of miR-675 were also reported and some of them will be mentioned below. Increasing data suggests a role for the full length H19 transcript as a decoy for micro-RNAs that modulates their availability and suppresses their activity [16–18]. H19 was also found to interact with transcription-repressors and guide them to specific loci; H19 binds the methyl-CpG–binding domain protein 1 MBD1 and recruits it to some of its targets (including H19’s reciprocally imprinted gene Igf2), thus enables the maintaining of repressive H3K9me3 histone marks in their loci [19]. H19 also interacts with enhancer of zeste homolog 2 (EZH2), a histone H3 Lys 27 (H3K27) methyltransferase, that represses gene expression as part of the Polycomb-Repressive Complex 2 (PRC2) [20]. In fibroblasts, H19 RNA itself is intracellularly sublocalized in lamellipodia and perinuclear regions through the binding of its 3’ to PTB (polypyrimidine tract-binding protein) and to 4 molecules of IGF2 mRNA-binding protein 1 (IGF2BP1) [21]. In gastric cancer, H19 was also found to bind P53 and partially inactivate it [22], and to bind ISM1 (Isthmin 1) in what seems to support a higher expression of this protein [14]. H19 was also found to bind the RNA binding protein K homology-type splicing regulatory protein (KSRP) [23]. This interaction supports KSRP targeting of unstable mRNAs, such as Myogenin, that leads to their subsequent decay. By that, H19 maintains an undifferentiated cellular state. H19 AND P53: A TIGHT RELATIONSHIP Since p53 is the major tumor suppressor gene in cancer, it is not surprising that H19 and p53 are mutually counter-regulated. Not only does P53 repress the promoter activity of the H19 gene [24, 25], it also epigenetically suppresses H19 expression in vivo by inducing DNA demethylation of the imprinting control region (ICR) upstream to the H19 gene [26]. We also have shown that hypoxia triggers H19 expression in p53 deficient cell lines [27], as will be later discussed. Moreover, it was recently found in bladder cancer cells that H19 derived miR-675 has a major role in inhibiting p53 and p53-dependent protein expression [28]. On the other hand, in gastric cancer cells H19 RNA was shown to interact with P53 protein, causing its partial inactivation [22], in what seems to be a negative feedback loop. As will be discussed below, this P53-H19 interplay is fundamental to understanding the role of H19 in tumorigenesis. H19 AND GENOMIC INSTABILITY Chromosomal instability (CIS) and overall genomic instability (including chromosomal aberrations and other mutations) were recognized as early as the beginning of the 20th century by Bovery as one of the most basic tumor-enabling attributes of cancer (reviewed in [29, 30]). In the somatic cell, chromosomal stability and a balanced number of paired chromosomes are essential for appropriate gene expression and chromosome segregation during the normal cell cycle. Thus, the cell cycle process is kept under strict molecular surveillance to prevent unbalanced segregation, replication of damaged DNA and incomplete replication [30]. However, when vital caretaker genes (“genome guardians”) and gatekeeper genes (“proliferation buffers”) such as p53, Rb and others are dysfunctional, as in tumor initiation, the

Read the complete text